10x Genomics Q1 EPS Estimate Decreased by Leerink Partnrs

10x Genomics, Inc. (NASDAQ:TXG) – Analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of 10x Genomics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings of ($0.54) per share for the quarter, down from their prior estimate of ($0.42). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for 10x Genomics’ current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for 10x Genomics’ Q2 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($1.49) EPS, FY2025 earnings at ($1.49) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($1.13) EPS, FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($0.82) EPS and FY2027 earnings at ($0.82) EPS.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%.

A number of other brokerages also recently issued reports on TXG. Leerink Partners downgraded shares of 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $25.00 to $12.00 in a research report on Thursday, February 13th. Barclays dropped their target price on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, February 1st. Citigroup lowered their price target on shares of 10x Genomics from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Finally, Canaccord Genuity Group lowered their price target on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $20.57.

10x Genomics Stock Performance

NASDAQ:TXG opened at $12.31 on Monday. 10x Genomics has a one year low of $10.80 and a one year high of $51.22. The firm has a market cap of $1.49 billion, a P/E ratio of -8.05 and a beta of 1.85. The firm has a 50-day simple moving average of $14.60 and a 200-day simple moving average of $17.28.

Hedge Funds Weigh In On 10x Genomics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Capital Performance Advisors LLP acquired a new stake in 10x Genomics during the third quarter worth about $35,000. Blue Trust Inc. increased its position in 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after purchasing an additional 1,025 shares during the last quarter. Signaturefd LLC increased its position in 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after purchasing an additional 1,452 shares during the last quarter. Venturi Wealth Management LLC increased its position in 10x Genomics by 1,108.9% during the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock worth $55,000 after purchasing an additional 2,240 shares during the last quarter. Finally, First Horizon Advisors Inc. increased its position in 10x Genomics by 53.3% during the third quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock worth $66,000 after purchasing an additional 1,012 shares during the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.